ATAGI recommendations on the use of Spikevax (Moderna) COVID-19 vaccine in children aged 6 to 11 years
- The Australian Technical Advisory Group of Immunisation (ATAGI) recommends using Spikevax or Moderna vaccine against COVID-19 in 6–11-year-old children.
- Based on a clinical study, Spikevax shows a strong immune response among children, reducing their susceptibility to COVID-19 development.
- ATAGI suggests immunization providers be vigilant for possible Moderna vaccine dosing mistakes for children.
- Paediatric vaccines against COVID-19 can also be co-administered with the other vaccines.
- The recommended vaccination in the aged group causes mild symptoms or is asymptomatic.